1. KRAS mutation and DNA repair and synthesis genes in non‑small‑cell lung cancer
   Vienna Ludovini et al, 2018, Molecular and Clinical Oncology CrossRef
2. Systemic treatments other than TKI: Reflections on chemotherapy, immunotherapy and antiangiogenic agents in ALK-driven NSCLC
   Alessandro Leonetti et al, 2021, Therapeutic Strategies to Overcome ALK Resistance in Cancer CrossRef
3. The impact of fusion genes on cancer stem cells and drug resistance
   Saurav Panicker et al, 2021, Molecular and Cellular Biochemistry CrossRef
4. Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomes
   Pascale Tomasini et al, 2016, Therapeutic Advances in Medical Oncology CrossRef
5. Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer
   Jaemin Jo et al, 2018, Yonsei Medical Journal CrossRef
6. Sustained Improvement in the Management of Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocation: Where Are We Running?
   Gianluca Spitaleri et al, 2023, Current Oncology CrossRef
7. Prise en charge des patients de stade avancé avec remaniement ALK : aujourd’hui et demain (« qui sera un autre jour... »)
   R. Descourt et al, 2017, Revue des Maladies Respiratoires Actualités CrossRef
8. Simultaneous VENTANA IHC and RT-PCR testing of ALK status in Chinese non-small cell lung cancer patients and response to crizotinib
   Chun-wei Xu et al, 2018, Journal of Translational Medicine CrossRef
9. What is Currently the Best for Adenocarcinoma without Driver Mutation?
   Cheol-Kyu Park et al, 2018, Tuberculosis and Respiratory Diseases CrossRef
10. Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape
    K.A. Olaussen et al, 2016, Annals of Oncology CrossRef